Sigma-1 Receptor Agonists and Their Clinical Implications in Neuropsychiatric Disorders
Yükleniyor...
Dosyalar
Tarih
2017
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Springer International Publishing Ag
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Accumulating evidence suggests that sigma-1 receptors play a role in the pathophysiology of neuropsychiatric diseases, as well as in the mechanisms of some selective serotonin reuptake inhibitors (SSRIs). Among the SSRIs, the order of affinity for sigma-1 receptors is as follows: fluvoxamine > sertraline > fluoxetine > escitalopram > citalopram >> paroxetine. Some SSRIs (e.g., fluvoxamine, fluoxetine and escitalopram) and other drugs (donepezil, ifenprodil, dehydroepiandeterone (DHEA)) potentiate nerve-growth factor (NGF)-induced neurite outgrowth in PC12 cells, and these effects could be antagonized by the selective sigma-1 receptor antagonist NE-100. Furthermore, fluvoxamine, donepezil, and DHEA, but not paroxetine or sertraline, improved phencyclidine-induced cognitive deficits in mice, and these effects could be antagonized by NE-100. Several clinical studies showed that sigma-1 receptor agonists such as fluvoxamine and ifenprodil could have beneficial effects in patients with neuropsychiatric disorders. In this chapter, the authors will discuss the role of sigma-1 receptors in the mechanistic action of some SSRIs, donepezil, neurosteroids, and ifenprodil, and the clinical implications for sigma-1 receptor agonists.
Açıklama
Anahtar Kelimeler
Donepezil, Ifenprodil, Fluvoxamine, Psychiatric diseases, Serotonin Reuptake Inhibitors, Improved Cognitive Impairments, Positron-Emission-Tomography, H-3 Ifenprodil Binding, Double-Blind, Delusional Depression, Schizophrenia Report, Tardive-Dyskinesia, Neurite Outgrowth, Therapeutic Drugs
Kaynak
Sigma Receptors: Their Role in Disease and As Therapeutic Targets
WoS Q Değeri
N/A
Scopus Q Değeri
Q3
Cilt
964
